Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Tirbanibulin Patent Expiration

Tirbanibulin is Used for treating actinic keratosis on the face or scalp. It was first introduced by Almirall Llc in its drug Klisyri on Dec 14, 2020.


Tirbanibulin Patents

Given below is the list of patents protecting Tirbanibulin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Klisyri US10323001 Compositions for modulating a kinase cascade and methods of use thereof Dec 28, 2027 Almirall
Klisyri US10617693 Methods of treating and/or preventing actinic keratosis Mar 12, 2038 Almirall
Klisyri US10669236 Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide Sep 07, 2038 Almirall
Klisyri US11497750 Methods of treating and/or preventing actinic keratosis Mar 12, 2038 Almirall
Klisyri US7300931 Compositions for treating cell proliferation disorders Feb 06, 2026 Almirall
Klisyri US7851470 Composition and methods for modulating a kinase cascade Feb 02, 2029 Almirall
Klisyri US8236799 Biaryl compositions and methods for modulating a kinase cascade Dec 28, 2025 Almirall
Klisyri US8980890 Compositions and methods of treating cell proliferation disorders Dec 28, 2025 Almirall


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳